Last reviewed · How we verify
Hepatic coma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Eryped | Erythromycin ethyl succinate | Arbor Pharms Llc | Macrolide | 1965-01-01 | ||
| Cortisporin | NEOMYCIN | Pfizer | Aminoglycoside Antibacterial | Transient receptor potential cation channel subfamily V member 1 | 1957-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Hepatic coma
- Arbor Pharms Llc · 1 drug in Hepatic coma
- Pfizer · 1 drug in Hepatic coma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hepatic coma:
- Hepatic coma treatment updates — RSS
- Hepatic coma treatment updates — Atom
- Hepatic coma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hepatic coma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hepatic-coma. Accessed 2026-06-10.
Related
- Hepatic coma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing